Rilpivirine regulatory update

Johnson & Johnson's Tibotec Pharmaceuticals Ltd. unit submitted an NDA to FDA for rilpivirine for use with other antiretrovirals in treatment-naive patients with HIV-1. TMC278 is a diarylpyrimidine no...